Loading
Before spending millions to turn a lab finding into a drug, spend a little to have an independent lab check it is real. Funders would reserve a small slice of money for exactly this.
Funders reserve 3% of research budgets for independent, pre-registered replications of high-impact preclinical findings that are about to receive translational investment (IND-enabling work, company formation, phase 1). Replication is done by contract labs or a network of academic 'replication cores' with blinded protocols agreed with the original authors. The Reproducibility Project: Cancer Biology found that many landmark effects were smaller or absent when repeated; catching this before translation saves far more than it costs.
Shares Patient-derived xenografts, Preclinical results do not reproduce, Patient-derived organoids, The valley of death between lab and product.
Shares CRISPR functional genomics, Preclinical results do not reproduce, Patient-derived organoids, The valley of death between lab and product.
Shares Patient-derived xenografts, CRISPR functional genomics, Patient-derived organoids.
Shares Patient-derived xenografts, Preclinical results do not reproduce, Patient-derived organoids, The valley of death between lab and product.
Shares Patient-derived xenografts, Preclinical results do not reproduce, The valley of death between lab and product.
Shares Patient-derived xenografts, Preclinical results do not reproduce, Patient-derived organoids.
Shares Patient-derived xenografts, CRISPR functional genomics, Preclinical results do not reproduce.
Shares A funded organoid and PDX panel as the go/no-go gate before IND-enabling money, Patient-derived xenografts, Preclinical results do not reproduce, Patient-derived organoids.